rNAPc2 (AB201)
clinical trial enrolled patients in US, Argentina & Brazil
Phase 2b

Topline data reported March 2022

A Late Stage Biopharma Company
Tailored Healthcare
Pharmacogenetic Precision Medicine for Cardiovascular Disease
30-60%

Individual patients respond differently to their disease and treatment.
Only 1/3 to 2/3 of common drug therapy is successful.

Atrial Fibrillation
An Epidemic Cardiovascular Disease
6.2 M

Estimated number of individuals diagnosed with AF in U.S. in 2016.

Unmet Medical Need
Safe and effective drug therapies for atrial fibrilation in patients with heart failure
Zero

There are currently no FDA approved drug therapies indicated for treating patients
with atrial fibrillation and heart failure with left ventricular ejection fraction (LVEF) >= 40%.

Gencaro™
Potentially the first genetically-targeted AF treatment
50%

Approximate % of U.S. population with genotype that responds most favorably to Gencaro™.

rNAPc2 (AB201)
clinical trial enrolled patients in US, Argentina & Brazil
Phase 2b

Topline data reported March 2022

A Late Stage Biopharma Company
Tailored Healthcare
Pharmacogenetic Precision Medicine for Cardiovascular Disease
30-60%

Individual patients respond differently to their disease and treatment.
Only 1/3 to 2/3 of common drug therapy is successful.

Atrial Fibrillation
An Epidemic Cardiovascular Disease
6.2 M

Estimated number of individuals diagnosed with AF in U.S. in 2016.

Unmet Medical Need
Safe and effective drug therapies for atrial fibrilation in patients with heart failure
Zero

There are currently no FDA approved drug therapies indicated for treating patients
with atrial fibrillation and heart failure with left ventricular ejection fraction (LVEF) >= 40%.

Gencaro™
Potentially the first genetically-targeted AF treatment
50%

Approximate % of U.S. population with genotype that responds most favorably to Gencaro™.

hex-our-focus

Our Focus

Precision Medicine

Precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient…

Cardiovascular Disease and Atrial Fibrillation

Cardiovascular disease is the No. 1 cause of death in the United States and a major economic burden on the healthcare system…

[+more]

Gencaro™ — An Unmet Need

pill

Gencaro™ is a pharmacologically unique beta-blocker and mild vasodilator that we believe has potential for the treatment of atrial fibrillation…

[+more]
hex-gencaro

Gencaro™